PMID- 20966921
OWN - NLM
STAT- MEDLINE
DCOM- 20101122
LR  - 20220408
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Print)
IS  - 1474-175X (Linking)
VI  - 10
IP  - 11
DP  - 2010 Nov
TI  - Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
PG  - 760-74
LID - 10.1038/nrc2947 [doi]
AB  - Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) 
      was first recognized in 2004 as a distinct, clinically relevant molecular subset 
      of lung cancer. The disease has been the subject of intensive research at both 
      the basic scientific and clinical levels, becoming a paradigm for how to 
      understand and treat oncogene-driven carcinomas. Although patients with 
      EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors 
      (TKIs), primary and acquired resistance to these agents remains a major clinical 
      problem. This Review summarizes recent developments aimed at treating and 
      ultimately curing the disease.
FAU - Pao, William
AU  - Pao W
AD  - Department of Medicine, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 
      Preston Research Building, Nashville, Tennessee 37232-6307, USA. 
      william.pao@vanderbilt.edu
FAU - Chmielecki, Juliann
AU  - Chmielecki J
LA  - eng
GR  - P30 CA068485-14/CA/NCI NIH HHS/United States
GR  - U54 CA143798/CA/NCI NIH HHS/United States
GR  - P50 CA090949-09/CA/NCI NIH HHS/United States
GR  - P01 CA129243-04/CA/NCI NIH HHS/United States
GR  - R01 CA121210-04/CA/NCI NIH HHS/United States
GR  - P30-CA68485/CA/NCI NIH HHS/United States
GR  - R01 CA121210/CA/NCI NIH HHS/United States
GR  - P50 CA090949/CA/NCI NIH HHS/United States
GR  - P30 CA068485/CA/NCI NIH HHS/United States
GR  - U54-CA143798/CA/NCI NIH HHS/United States
GR  - R01-CA121210/CA/NCI NIH HHS/United States
GR  - CA90949/CA/NCI NIH HHS/United States
GR  - P01-CA129243/CA/NCI NIH HHS/United States
GR  - P01 CA129243/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20101022
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Drug Resistance, Neoplasm
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - *Mutation
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
PMC - PMC3072803
MID - NIHMS281118
COIS- Competing interests statement The authors declare competing financial interests; 
      see Web version for details.
EDAT- 2010/10/23 06:00
MHDA- 2010/12/14 06:00
PMCR- 2011/04/08
CRDT- 2010/10/23 06:00
PHST- 2010/10/23 06:00 [entrez]
PHST- 2010/10/23 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2011/04/08 00:00 [pmc-release]
AID - nrc2947 [pii]
AID - 10.1038/nrc2947 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2010 Nov;10(11):760-74. doi: 10.1038/nrc2947. Epub 2010 Oct 22.